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Abstract
Background: Obesity is a global phenomenon and is associated with various types of cancer, including colon cancer. 
There is a growing interest for safe and effective bioactive compounds that suppress the risk for obesity-promoted 
colon cancer. Resveratrol (trans-3, 4', 5,-trihydroxystilbene), a stilbenoid found in the skin of red grapes and peanuts 
suppresses many types of cancers by regulating cell proliferation and apoptosis through a variety of mechanisms, 
however, resveratrol effects on obesity-promoted colon cancer are not clearly established.
Methods: We investigated the anti-proliferative effects of resveratrol on HT-29 and SW480 human colon cancer cells in 
the presence and absence of insulin like growth factor-1 (IGF-1; elevated during obesity) and elucidated the 
mechanisms of action using IGF-1R siRNA in HT-29 cells which represents advanced colon carcinogenesis.
Results: Resveratrol (100-150 μM) exhibited anti-proliferative properties in HT-29 cells even after IGF-1 exposure by 
arresting G0/G1-S phase cell cycle progression through p27 stimulation and cyclin D1 suppression. Treatment with 
resveratrol suppressed IGF-1R protein levels and concurrently attenuated the downstream Akt/Wnt signaling pathways 
that play a critical role in cell proliferation. Targeted suppression of IGF-1R using IGF-1R siRNA also affected these 
signaling pathways in a similar manner. Resveratrol treatment induced apoptosis by activating tumor suppressor p53 
protein, whereas IGF-1R siRNA treatment did not affect apoptosis. Our data suggests that resveratrol not only 
suppresses cell proliferation by inhibiting IGF-1R and its downstream signaling pathways similar to that of IGF-1R siRNA 
but also enhances apoptosis via activation of the p53 pathway.
Conclusions: For the first time, we report that resveratrol suppresses colon cancer cell proliferation and elevates 
apoptosis even in the presence of IGF-1 via suppression of IGF-1R/Akt/Wnt signaling pathways and activation of p53, 
suggesting its potential role as a chemotherapeutic agent.
Background
Nearly two-thirds of Americans are overweight or obese
[1], and obesity elevates the risk for colon cancer [2-9],
the second leading cause of cancer deaths in the United
States [10]. Surgery, radiation and chemotherapy alone or
in combination are the most common methods to treat
different types of cancers, including colon cancer. These
conventional therapies can prolong a patient's life span,
but they may cause serious side-effects. Since colon can-
cer takes 10-20 years to progress beyond initiation stage
[11], there exists an opportunity to prevent colon cancer
progression through appropriate nutrition and exercise.
A recent meta-analysis found that a 5 kg/m2 increase in
body mass index (BMI) raises colon cancer risk by 24% in
men [12]. Thus, it is imperative to intensify our efforts to
better understand the pathogenesis of colon cancer dur-
ing obese conditions and try to develop novel, evidence-
based and safe approaches for its prevention and treat-
ment.
* Correspondence: Jairam.Vanamala@colostate.edu
1 Department of Food Science and Human Nutrition, 226 Gifford Building, 
Colorado State University, Fort Collins, CO, 80523-1571, USA
Full list of author information is available at the end of the articleVanamala et al. BMC Cancer 2010, 10:238
http://www.biomedcentral.com/1471-2407/10/238
Page 2 of 14
The adipokines and growth factors are involved in a
wide range of physiological processes including general
homeostasis, cell growth, metabolism, and are frequently
deregulated during obese conditions [13]. Over-activa-
tion of the IGF system is also commonly observed in
obese conditions and plays a critical role in obesity-pro-
moted colon cancer [14]. IGF-1 has been linked to tumor
growth in adults in a number of studies, including two
large trials jointly conducted by Harvard Medical School
and Brigham and Women's Hospital. A six-year study of
32,826 nurses, found that those with the highest levels of
IGF-1 had a two-and-a-half times greater risk of colorec-
tal cancer; another study of 14,916 male physicians also
concluded that men run the same risk [15,16]. This IGF
system includes ligands, receptors, and ligand-binding
proteins (IGFBPs). Over-nourishment and chronic
hyperinsulinemia observed in obese conditions may
deregulate colonocyte growth kinetics, as elevated insulin
and suppressed IGFBP-1, and IGFBP-2 levels increase the
pool of free or bioavailable IGF-1. A larger pool of bio-
available IGF-1 can activate the IGF-1 receptor (IGF-1R),
thus may stimulate colonocyte proliferation [14,17-19].
IGF-1R is over expressed during colon carcinogenesis,
with the highest expression in the proliferating cells at the
base of the colonic crypts [20]. Upon IGF-1 binding, IGF-
1R activates the PI3K/Akt cascade, which promotes G1 to
S cell cycle progression [21] and elevates cell proliferation
[22]. One of the pathways activated by the PI3K/Akt cas-
cade is the Wnt/β-catenin pathway [23]. The Wnt/β-
catenin pathway plays a central role in elevating colono-
cyte proliferation [24] and suppressing apoptosis in both
humans and rodent models of experimentally induced
colon cancer [25,26]. Akt phosphorylates and inactivates
GSK3β, allowing β-catenin, a downstream effector of
Wnt pathway to translocate into the nucleus where it
binds to TCF-4. The β-catenin/TCF-4 complex consti-
tutes the master switch that regulates colonocyte prolif-
eration [27].
Resveratrol, a stilbenoid derived mainly from the skin
of grapes, is a potential dietary compound against various
cancers - breast, colon, etc., in vitro and in vivo [28,29].
Resveratrol works at a very low concentration in vivo (< 2
μM). However, in vitro studies require a much higher
concentration (at least 25-50 μM) to elicit similar chemo-
therapeutic action [30]. In a variety of cancer cells, res-
veratrol suppressed critical components of the PI3K/Akt
pathway [31-33]. Recent reports suggest that resveratrol
also promotes phosphorylation of p53 in a dose and time-
dependent manner in human breast cancer cells [34].
This impairs ability of p53 to bind to its negative regula-
tor, MDM2 [35]. Thus p53 is active and can cause either
cell cycle arrest or apoptosis [34,35]. P53 suppresses IGF-
1R gene expression [36,37] in Saos-2 (osteosarcoma-
derived cells) and RD (rhabdomyosarcoma-derived cells)
cells [38]. Resveratrol also has been shown to suppress
IGF-1 levels in mice consuming a high-fat diet [39]. Low
concentrations of resveratrol (< 40 μM) have also shown
to inhibit Wnt signaling in colon cancer cells [29]. How-
ever, the inhibitory efficacy of resveratrol against IGF-1
induced colonocyte proliferation and the molecular
mechanisms of its action are not yet fully elucidated. We
hypothesized that resveratrol suppresses colon cancer
cell proliferation and elevates apoptosis after IGF-1 expo-
sure through activation of p53 and suppression of IGF-
1R/Akt/Wnt signaling pathways. In order to establish the
efficacy of resveratrol against IGF-1 induced colon cancer
growth, we utilized HT-29 and SW480 (IGF-1R constitu-
tively active) human colon cancer cell lines and treated
them with/without IGF-1 and/or resveratrol.
In this study, resveratrol at 100-150 μM suppressed
IGF-1R/Akt and Wnt/β-catenin signaling pathway pro-
teins in the HT-29 colon cancer cell lines. Similar results
were observed with IGF-1R siRNA treatment. Resvera-
trol also activated p53 protein and suppressed levels of
sp1, a protein that transcriptionally activates IGF-1R.
Resveratrol elevated unphosphorylated (active) form of
forkhead transcription factor (FKHRL1 protein), thereby
contributing to cell cycle arrest. Overall our results dem-
onstrate that resveratrol (i) suppresses IGF-1R levels,
thus, downregulates Akt and Wnt/β-catenin signaling; (ii)
elevates levels of active FKHRL1 and p27, and concomi-
tantly suppresses cyclin D1 levels and (iii) activates p53
and suppresses sp1, thus suppressing cell cycle progres-
sion and elevating apoptosis in vitro even in the presence
of free mitogenic IGF-1.
Methods
Chemicals
IGF-1 was obtained from the R&D Systems (Minneapolis,
MN). Fetal bovine serum (FBS) was purchased from the
Thermo Fisher Scientific (Pittsburgh, PA). All other cell
culture supplies and resveratrol were purchased from the
Sigma Chemical Company (St. Louis, MO).
Cell lines
HT-29 and SW480 colon cancer cell lines were obtained
from the American Type Culture Collection (Manassas,
V A ) .  C e l l s  w e r e  m a i n t a i n e d  a t  3 7 ° C  w i t h  5 %  C O 2 and
grown in Dulbecco's Modified Eagle's Medium F-12
(DMEM/F-12) supplemented with 2.2 g/L sodium bicar-
bonate, 0.2 g/L bovine serum albumin, 50 mL/L fetal
bovine serum and 10 mL/L antibiotic and antimycotic
solution.
Design of siRNA against IGF-1R
IGF-1R siRNA and inverted control duplex were
designed as described [40] and were purchased from
Ambion (Austin, TX). The sequences of IGF-1R siRNAVanamala et al. BMC Cancer 2010, 10:238
http://www.biomedcentral.com/1471-2407/10/238
Page 3 of 14
duplex are: sense strand, 5'-CGACUAUCAGCAGCU-
GAAGTT-3'; antisense strand, 5'-CUUCAGCUGCU-
GAUAGUCGTT-3'. It is homologous to 168-186
nucleotides of human IGF-1R transcript. 5'-GAAGUC-
GACGACUAUCAGCTT-3' and 5'-GCUGAUAGUCGU-
CGACUUCTT-3' are sense and antisense sequences of
inverted control duplex, respectively. The construct
against IGF-1R mRNA was referred as IGF-1R siRNA,
the inverted control or non specific siRNA was referred
as siRNA control, and GAPDH siRNA was used as posi-
tive control.
siRNA transfection
HT-29 cells were seeded in DMEM/F-12 supplemented
with 5% fetal bovine serum in six-well plates. Cells at 50%
confluence were transfected with IGF-1R siRNA
duplexes after 20-24 h, using Dharma FECT 4 reagent
(Dharmacon Inc., CO) in antibiotic- and serum-free
DMEM/F-12 medium. Three concentrations (50, 75 and
100 nM) of IGF-1R siRNA duplexes, 100 nM non specific
siRNA and 100 nM GAPDH siRNA were used for initial
optimization, and for subsequent assays 75 nM siRNA
was used, as there was no difference in IGF-1R inhibition
between 75 and 100 nM concentrations. Cells were har-
vested after 72 h of transfection using 1× lysis buffer, and
then protein was extracted. The knockdown of IGF-1R
was confirmed by Western blotting.
Cell proliferation assay
Cells were plated at a density of 5 × 104 cells per well in
12-well plates in Dulbecco's modified Eagle's medium F-
12 (DMEM/F-12) containing 2.5% charcoal-stripped fetal
bovine serum. After 24 h, cells were treated with DMSO
(solvent control), 10 nM IGF-1 and/or resveratrol (150
μM), and anti-proliferative properties of resveratrol were
evaluated after 24, 48 and 72 h. As colonocytes have
greater exposure to the bioavailable IGF-1 in obese con-
dition, in the combined treatments (for all the studies in
the manuscript), the cells were pre-incubated with IGF-1
(10 nM) for 5 minutes followed by resveratrol treatment
to check the effect of resveratrol when the cells are
already primed to proliferate. Dose response studies with
IGF-1 (5 - 20 nM) showed that 10 and 20 nM IGF-1 treat-
ments did not differ (p < 0.05) in inducing cell prolifera-
tion (data not shown). Thus, we used 10 nM
concentration of IGF-1 for subsequent experiments. In
case of siRNA experiment, after 24 h of transfection, cells
were treated with IGF-1 at 10 nM and/or resveratrol at
150 μM for 24 h. Cells were counted after 24 and 48 h
using a Z1 Coulter Counter, Beckman Coulter (Fullerton,
CA). Each experiment was carried out in triplicate, and
results were expressed as mean ± SE.
TUNEL assay
The TUNEL (terminal transferase dUTP nick end label-
ing) assay was performed to determine the effect of res-
veratrol/IGF-1R siRNA on apoptosis. Cells (4 × 104) were
seeded in four-chambered glass slides and after treatment
for 12 h, the in situ cell death detection kit, POD (peroxi-
dase), Roche Applied Science (Indianapolis, IN) was used
according to the instruction manual protocol for fixed
cells to identify apoptotic cells. Slides incubated without
terminal deoxynucleotidyl transferase (TdT) served as a
negative control, and slides treated with 1000 U DNAse I/
ml for 10 min before TdT exposure served as a positive
control. After the incubation of cells with POD and
diaminobenzidene substrate, the percentage of apoptotic
cells was calculated by counting the stained cells in 12
fields, each containing at least 50 cells [41].
Fluorescence-activated cell sorting analysis (FACS)
HT-29 cells were plated at a density of 15 × 105 cells per
100 mm plate and after 18 h treatment with either the
control (DMSO), IGF-1 (10 nM), resveratrol (50 or 150
μM), or their combina tions, cells were trypsinized and
centrifuged. The pellet was resuspended with 1 ml of PI
staining buffer containing 4 mM sodium citrate, 0.1% Tri-
ton X-100, 50 μg/ml propidium iodide and 200 μg/ml
RNAse and incubated for 10 min at 37°C in the dark, and
the final concentration of sodium chloride was adjusted
to 0.15 M. Cells were analyzed using FACSCalibur flow
cytometer and CellQuest Acquisition software, Becton
Dickinson immunocytometry systems (San Jose, CA).
Results were reported as per cent cells in each phase of
the cell cycle.
Western blot analysis
HT-29 cells were seeded at a density of 1.5 × 105 cells/mL
in Dulbecco's Modified Eagle's Medium F-12 with 2.5%
charcoal-stripped fetal bovine serum for 24 h. Cells were
treated with control, IGF-1, different concentrations of
resveratrol (50, 100 and 150 μM) with and without IGF-1
(10 nM) for 24 h. Protein was extracted into a high-salt
buffer containing 1% protease inhibitor cocktail from
Sigma-Aldrich (St. Louis, MO), and protein concentra-
tions were determined by a BCA Protein Assay kit from
Pierce (Rockford, IL). Cell lysates (30 μg) were incubated
at 98°C for 5 min and separated by Novex® 8-16% Tris-
HCl gels from Invitrogen (Carlsbad, CA) at 120 V for 2 h
in 1 × running buffer [25 mmol/L Tris, 192 mmol/L gly-
cine, 0.1% SDS (pH 8.3)], and electrophoretically trans-
ferred to Immun-Blot PVDF membranes from Bio-Rad
Laboratories (Hercules, CA) at 95 V for 35 min in 2×
Tris-glycine transfer buffer (Novex, LC3675, Invitrogen)
with 0.025% SDS. PVDF membranes were blocked with
2% bovine serum albumin from Fisher Scientific (Pitts-
burg, PA) for 1 h at room temperature. The membranesVanamala et al. BMC Cancer 2010, 10:238
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were incubated with rabbit polyclonal anti-sp1 antibody,
Upstate Biotechnology (1:1,000; Lake Placid, NY), goat
polyclonal anti-β-catenin antibody, rabbit polyclonal
anti-GSK3β antibody, mouse monoclonal anti-cyclin D1
antibody, goat polyclonal anti-β-actin antibody, mouse
monoclonal anti-MDM2 antibody, rabbit polyclonal anti-
p27 antibody, rabbit polyclonal anti-IGF-1Rβ antibody
and rabbit polyclonal anti-FKHRL1 antibody, all from
Santa Cruz Biotechnology (1:500; Santa Cruz, CA) for 2 h
at room temperature. Membranes were subsequently
probed with bovine anti-goat, goat anti-rabbit or goat
anti-mouse IgG-HRP conjugate secondary antibody,
Santa Cruz Biotechnology (all 1:100,000). Target proteins
were detected with Super Signal West Dura Extended
Duration Substrate from Pierce (Rockford, IL). Mem-
branes were scanned with ChemiDoc XRS (Bio-Rad)
using Quantity One software (Bio-Rad) and the band
intensities were calculated using Image J software, and
normalized to β-actin, a loading control.
Statistical analysis
Analysis of variance and Fisher least square difference at
5% significance level determined the degree of signifi-
cance among treatments. The results were expressed as
mean ± SE for three replicates for each treatment.
Results
Growth stimulatory/inhibitory effects of IGF-1 and 
resveratrol
Growth stimulatory effects of IGF-1 and the anti-prolifer-
ative effects of resveratrol were investigated using HT-29
and SW-480 colon cancer cells. Human colon cancer cells
were grown in DMEM with 2.5% charcoal-stripped
serum for 24 h and treated with DMSO (solvent control),
IGF-1 (10 nM), and different concentrations of resvera-
trol (50, 100 and 150 μM). Our results demonstrated that
resveratrol suppresses the colon cancer cell proliferation
even when the cells are primed to proliferate with IGF-1.
After 72 hours, IGF-1 (10 nM) treatment increased HT-
29 cell proliferation (87%) confirming its growth stimula-
tory effects (Figure 1). Treatment of these cells with res-
veratrol suppressed cell proliferation (up to 95%)
compared to the control. Moreover, pre-incubation of
HT-29 cells with IGF-1 for 5 minutes followed by treat-
ment with resveratrol also resulted in suppressed cell
proliferation (up to 94%) (Figure 1). The colon cancer cell
number in the combination of IGF-1 and resveratrol
treatment was similar to resveratrol treatment alone.
Thus, resveratrol might be a potent inhibitor of cell pro-
liferation even in the presence of IGF-1. Similar results
were obtained using SW-480 colon cancer cells (Figure 2).
Resveratrol suppresses cell proliferation to levels below
control even in the presence of IGF-1. This may be due to
resveratrol's combined effect on IGF-1R signaling sup-
pression, induction of apoptosis and alteration of multi-
ple other pathways. Cytotoxicity assays established that
resveratrol did not induce necrosis at the doses used for
this study (data not shown). Since HT-29 colon cancer
cells represent advanced stages of colorectal cancer, fur-
ther experiments were conducted using HT-29 cells
[42,43].
Fluorescence-activated cell sorting analysis (FACS)
technique was used to determine the effect of resveratrol
on cell cycle progression in HT-29 cells. Figure 3 illus-
trates the distribution of HT-29 cells in the G0/G1, S and
G2/M phases after IGF-1 (10 nM) and/or resveratrol (50
μM or 150 μM) treatments. IGF-1 treatment had lower
percentage of HT-29 cells in the G0/G1 phase (42.6%),
whereas resveratrol elevated the percentage of HT-29
cells in the G0/G1 phase (72.9%), compared to the control.
Combined treatments of IGF-1 and resveratrol also
caused an increase in the percentage of cells in the G0/G1
phase (69.7%) similar to resveratrol treatment alone. Res-
veratrol treatment at 50 μM also had numerical increase
in cells in G0/G1 phase, however it was not significantly
different from the control. These results suggest that res-
veratrol targets G0/G1 to S phase progression to arrest
IGF-1 induced HT-29 cell proliferation.
Efficacy of IGF-1R siRNA in suppressing IGF-1 stimulated 
growth of colon cancer cells
To determine whether the IGF-1 induced growth stimu-
latory properties are through IGF-1R, HT-29 cells were
transfected with either non specific siRNA (siRNA con-
trol) or IGF-1R siRNA (75 nM) and after 24 h treated
with DMSO (solvent control), IGF-1 (10 nM) and/or res-
veratrol (150 μM). IGF-1R siRNA suppressed colon can-
cer cell proliferation, and the cell numbers were lower
than the siRNA control group (Figure 4). IGF-1 treatment
could not increase the number of cells in IGF-1R siRNA
transfected group, but it did increase (p < 0.05) the cell
proliferation in non specific siRNA transfected cells com-
pared to the solvent control, confirming that IGF-1
induced proliferation is through IGF-1R. IGF-1R siRNA
along with resveratrol suppressed proliferation compared
to IGF-1R siRNA alone. The effect of resveratrol on IGF-
1R is similar to the inhibitory effects of IGF-1R siRNA on
the proliferation of colon cancer cells via suppressing
IGF-1R and the downstream kinases, and the Wnt/β-
catenin signaling pathway.
Resveratrol but not IGF-1R siRNA induces apoptosis in HT-
29 cells
Induction of apoptosis by resveratrol and/or IGF-1R
siRNA in HT-29 cells was analyzed using TUNEL (termi-
nal transferase dUTP nick end labeling) assay. Cells were
grown in four chambered glass slides and transfectedVanamala et al. BMC Cancer 2010, 10:238
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with either non specific siRNA (siRNA control) or IGF-
1R siRNA and treated with IGF-1 and/or resveratrol.
IGF-1R siRNA did not alter apoptosis suggesting that
IGF-1R siRNA suppresses colon cancer cell growth pri-
marily through anti-proliferative and/or senescence
mechanisms. Resveratrol induced 30% and 25% of apop-
totic cell death in the absence and presence of IGF-1,
respectively, in the siRNA control group (Figure 5A).
These results suggest that unlike IGF-1R siRNA, resvera-
trol inhibits growth of colon cancer cells by not only sup-
pressing proliferation but also elevating apoptosis. In the
case of IGF-1R siRNA transfected cells, the percentage
induction of apoptosis with resveratrol, alone or in the
presence of IGF-1, was about 40% and 30%, respectively
(p < 0.05, Figure 5A). To further confirm the apoptotic
cell death by resveratrol, we measured PARP cleavage, the
hallmark of apoptosis, using Western blotting. Figure 5B
shows the induction of PARP cleavage as accumulation of
cleavage fragment (89 kDa) in resveratrol treated HT-29
cells.
Figure 1 Growth stimulatory and inhibitory effects of IGF-1 and resveratrol, respectively in HT-29 colon cancer cells. HT-29 cells were treated 
with IGF-1 (I; 10 nM) and/or resveratrol (R; 50, 100, and 150 μM) for 24, 48 and 72 h, and cell numbers were determined using a Z1 Coulter counter. 
Results were expressed as mean ± SE for three experiments at each time point. Mean proliferation (p < 0.05) lower than that of control treatment are 
indicated: a, b and c for 24, 48 and 72 h, respectively and higher (p < 0.05) than that of control are indicated: x, y and z for 24, 48 and 72 h, respectively.
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Resveratrol down regulates IGF-1R signaling proteins
To investigate whether resveratrol/IGF-1R siRNA
induced growth arrest of the human colon cancer cell
lines was associated with IGF-1R downstream signaling,
lysates from cells treated with IGF-1, resveratrol, and
IGF-1R siRNA were subjected to western blot analysis.
IGF-1 is a known cell cycle progression factor that acti-
vates important downstream kinases, PI3K/Akt. IGF-1
treatment elevated pAkt, pGSK3β, and cyclin D1 levels
resulting in augmented proliferation of HT-29 colon can-
cer cells (Figure 6B). IGF-1R knockdown using siRNA
suppressed the levels of IGF-1R protein and concomi-
tantly suppressed the downstream kinases, pAkt and
pGSK3β, and cyclin D1 (Figure 6A). Similar results were
observed with resveratrol alone or in combination with
IGF-1 (Figure 6B). Cyclin D1 is an important protein for
cell cycle progression and its levels are dependent on β-
catenin nuclear translocation [44]. Figure 7A shows lower
levels of nuclear β-catenin in resveratrol treated cells
compared to control or IGF-1 treated cells. Interestingly,
IGF-1 pretreatment potentiated the resveratrol suppres-
sion of nuclear β-catenin levels.
Sp1 is a critical mediator of IGF-1R transcription and
upregulates IGF-1R promoter activity [38,45]. Figure 7B
illustrates the effect of IGF-1 and resveratrol on sp1 pro-
tein levels. Resveratrol downregulated sp1 protein and
suppressed the levels of IGF-1R (Figure 7B, 6B). These
results suggest that IGF-1R is an important molecular
target for resveratrol in the suppression of colon cancer
cell proliferation and also suggests the role of resveratrol
in regulating IGF-1R transcription. To elucidate whether
or not resveratrol affects the insulin receptor (IR), we
determined IR protein levels. We did not observe down
regulation of IR receptor, even with a high concentration
of resveratrol (data not shown), which confirms selective
targeting of IGF-1R by resveratrol.
Figure 2 IGF-1 elevates and resveratrol suppresses cell proliferation in SW480 colon cancer cells. SW480 cells were treated with IGF-1 (10 nM) 
and/or resveratrol (150 μM) for 24, 48 and 72 h and cell numbers were determined using a Z1 Coulter counter. Results were expressed as mean ± SE 
for three experiments at each time point. Mean proliferation significantly lower than that of control treatment are indicated: a, b and c for 24, 48 and 
72 h, respectively (p < 0.05) and higher than that of control are indicated: x, y and z for 24, 48 and 72 h, respectively (p < 0.05).
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Resveratrol activates tumor suppressor protein p53 and 
elevates activated forkhead transcription factor 1 levels
A critical tumor suppressor gene p53 regulates DNA
repair, cell cycle progression and apoptosis [46]. In cancer
cells, p53 is generally degraded due to ubiquitination by
MDM2, a negative regulator of the p53 [46]. Our results
show that resveratrol activates p53 and suppresses
MDM2 levels in colon cancer cells (Figure 7C). The
observed reduction in IGF-1R protein levels in resvera-
trol treatment may be in part due to p53 activation,
because p53 is involved in transcriptional suppression of
the IGF-1R gene, and regulation of the IGF-1R promoter
activity through suppression of sp1 [38,45].
FKHRL1, a member of the family of forkhead transcrip-
tion factors, is a transcriptional activator that induces cell
cycle arrest or upregulates apoptosis depending upon cel-
lular context and type of stress [47]. Unphosphorylated
FKHRL1 was upregulated in cells treated with resveratrol
(Figure 7D). P27, a downstream target of FKHRL1, is a
cell cycle regulator protein that binds to and inactivates
cyclin D1 [47]. P27 was also upregulated by resveratrol
treatment (Figure 7D). Combined, these results suggest
that resveratrol may cause cell cycle arrest at the G0/G1-S
phase transition via FKHRL1 pathway by upregulating
p27 and inactivating cyclin D1.
Discussion
P h yt oc h e m i ca ls  a ff ect  m yri a d  i n t r a c e l l u la r  ta r g e ts;  i t  is
this quality that often makes them desirable as chemo-
therapeutic agents against cancer [17,41,48-50]. Studies
in both in vitro and in vivo models suggest that resvera-
trol can suppress components of the IGF system [32,33],
which in turn may suppress cell proliferation and elevate
apoptosis. Our results indicate that resveratrol sup-
presses cell proliferation and induces apoptosis even
when the cells are primed to proliferate with IGF-1, a
mitogen that is highly bioavailable during obesity. Resver-
atrol exerts its anti-proliferative and pro-apoptotic prop-
erties through suppression of IGF-1R/Akt/Wnt pathways
and activation of p53 signaling.
Emerging evidence suggests that members of the insu-
lin-like growth factors (IGFs) family, including IGF-I,
IGF-II, IGF-IR, and the IGF-binding proteins (IGFBPs)
play a central role in the development and progression of
a variety of cancers during obesity, including colon cancer
[51]. IGF-1 binding to IGF-1R stimulates downstream
Figure 3 Effect of resveratrol on cell cycle progression of IGF-1 treated colon cancer cells. HT-29 cells were plated at a density of 15 × 105 cells 
per 100 mm plate and after 18 h treatment with the vehicle (DMSO), IGF1 (I; 10 nM) and/or resveratrol (R; 50 or 150 μM); they were analyzed by Fluo-
rescence-activated cell sorting analysis (FACS). Results are expressed as % of cells in each phase. Numbers on top of the bars represent percent cells 
in respective phases in each treatment group.
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proliferating pathways such as the PI3K/Akt [52] and Ras
signaling [23] resulting in increased human colon cancer
cell proliferation, thus suppressing IGF-1R might attenu-
ate proliferation. Resveratrol suppressed IGF-1 stimu-
lated HT-29 colon cancer cell proliferation. Pre-
incubation with IGF-1 followed by resveratrol suppressed
proliferation lower than that of control and was similar to
that of treatment with resveratrol alone. This may be due
to resveratrol's combined effect on IGF-1R signaling sup-
pression, apoptosis and multiple other pathways. Similar
results were also observed in SW480 cells with constitu-
tively expressed IGF-1R. Indeed, FACS results show that
treatment with resveratrol alone or in combination with
IGF-1 arrests G0/G1-S phase progression. These results
indicate that resveratrol may suppress cellular prolifera-
tion even when colon cancer cells are already exposed to
high levels of IGF-1 during obese conditions.
Knockdown of IGF-1R using IGF-1R siRNA also sup-
pressed cell proliferation comparable to resveratrol treat-
ment even in the presence of IGF-1. Resveratrol induced
apoptosis in HT-29 cells, but IGF-1R siRNA had no effect
on apoptosis. However, resveratrol treatment had greater
percent apoptosis in IGF-1R siRNA transfected cells
compared to non specific siRNA. Whether provided
alone or following incubation with IGF-1, resveratrol
suppressed the IGF-1R/Akt/GSK3β signaling pathway
and concomitantly suppressed nuclear translocation of β-
catenin. Once inside the nucleus, β-catenin binds to TCF-
4 and transcriptionally activates proliferative (e.g., cyclin
D1) genes. Cyclin D1 is known to function as a regulatory
subunit of CDK4 or CDK6 (cyclin dependant kinases),
whose activity is required for G0/G1-S phase transition
[53]. Interestingly, IGF-1 pretreatment potentiated the
resveratrol suppression of nuclear β-catenin. This may be
because resveratrol targets actively proliferating cells and
IGF-1 promotes number of proliferating cells via G1 to S
cell cycle progression. This is in accordance with greater
resveratrol suppression of proliferation in IGF-1 pre-
treated cells. IGF-1R siRNA transfection also affected the
downstream Akt/GSK3β/β-catenin pathway similar to
that of resveratrol. These results suggest that resveratrol
exerts its anti-proliferative properties through suppres-
sion of IGF-1R, and is similar to IGF-1R siRNA in sup-
Figure 4 Effect of IGF-1R knockdown and/or resveratrol on proliferation of colon cancer cells in vitro. Cells were seeded in 12-well plates and 
transfected with IGF-1R siRNA duplexes (75 nM) or non specific siRNA (siRNA control). After 24 h of transfection, cells were treated with IGF-1 (10 nM) 
and/or resveratrol (150 μM) for 24 h. Cell numbers were determined using a Coulter counter. * indicates suppression or elevation (p < 0.05) by treat-
ments compared to non specific siRNA control treatment.
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Figure 5 Effects of Resveratrol and treatment on apoptosis. A - Resveratrol but not IGF-1R siRNA induces apoptosis in HT-29 cells. Percent-
age induction of apoptosis was determined by TUNEL assay. The rate of apoptosis was expressed as a percentage of the total cells counted. Results 
are expressed as mean ± SE for the different treatments in both non specific siRNA and IGF-1R siRNA transfected cells. * indicates significant elevation 
compared to solvent control (DMSO). $indicates elevation (p < 0.05) by treatments compared to non specific siRNA control. B - Resveratrol treatment 
elevated cleaved PARP, a hallmark of apoptosis. Cells were treated with resveratrol (50, 100 and 150 μM) alone or IGF-1 (10 nM) for 5 minutes fol-
lowed by resveratrol at different concentrations and analyzed by western blot as described in materials and methods. Similar results were obtained 
in duplicate experiments.
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Figure 6 Effect of IGF-1R siRNA (A), and resveratrol (B) on IGF-1R/Wnt signaling pathway proteins. A - HT-29 cells were treated with DMSO 
(control), non specific siRNA (siRNA control; 100 nM), positive siRNA (GAPDH siRNA; 100 nM) and IGF-1R siRNA (50, 75 and 100 nM) for 72 h. B - HT-29 
cells were treated with DMSO, IGF-1 (10 nM) and/or resveratrol (150 μM) for 24 h. In case of both A and B, whole cell lysates were analyzed by western 
blotting as described in materials and methods. Proteins were detected by using specific antibodies. Band intensities normalized to loading control 
were indicated on top of the respective band (A). Similar results were obtained in duplicate experiments.
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pressing HT-29 cell proliferation but not in the induction
of apoptosis.
In normal, unstressed cells, p53 levels are low due to
continuous MDM2-mediated ubiquitination and degra-
dation. IGF-1R activation further ensures low levels of
p53 as the resulting increase in phosphorylated Akt
increases the ubiquitination activity of MDM2 [46]. How-
ever, p53 phosphorylation prevents p53 from binding to
its negative regulator MDM2 [35]. Reports suggest that
p53 activation suppresses the IGF-1R mRNA levels [36].
The observed reduction in IGF-1R protein levels in res-
veratrol treatment may be in part due to p53 activation,
because p53 is involved in transcriptional suppression of
the IGF-1R gene, and regulation of the IGF-1R promoter
activity through suppression of sp1 [38,45]. Resveratrol
treatment exerted anti-proliferative effects without sup-
pressing IR levels (data not shown), suggesting that res-
veratrol specifically targets IGF-1R in suppressing cell
proliferation by activating p53 and suppressing sp1 levels.
Transcriptional activation of FKHRL1 proteins is regu-
lated by the serine/threonine kinase Akt, which phospho-
rylates FKHRL1 and inactivates it [54,55]. Induction of
apoptosis or withdrawal of growth factors stimulates
dephosphorylation and nuclear translocation of FKHRL1,
leading to FKHRL1-induced gene-specific transcriptional
activation [54,56-60]. We studied the effect of resveratrol
on FKHRL1. Resveratrol caused up-regulation of unphos-
phorylated active form of FKHRL1. This active form of
FKHRL1 translocates to the nucleus and has been shown
to induce apoptosis by upregulation of Fas-ligand expres-
sion and activation of the death receptor pathway [61].
P27 is a direct downstream target of FKHRL1 and over
expression of cytoplasmic FKHRL1 concomitantly ele-
vates p27, an inhibitor of cyclin D1, thereby affecting cell
cycle progression [47,61]. Our data suggests that resvera-
trol up-regulates FKHRL1 in the cytoplasm and also
increases p27 levels. Over expression of FKHRL1 resulted
in an increased expression of p27 and thus potential inhi-
bition of cyclin D1, and concurrent suppression of cell
Figure 7 Suppressed human colon cancer cell proliferation and elevated apoptosis by resveratrol involves multiple molecular targets. Ef-
fects of resveratrol (R; 150 μM) and/or IGF-1 (I; 10 nM) on expression of A, β-catenin; B, sp1; C, MDM2 and p53; D, FKHRL1, p27 and cyclin D1; in HT-29 
cells. HT-29 cells were treated with IGF-1 and/or resveratrol for 24 h. Whole cell lysates were analyzed by western blotting as described in materials 
and methods. Blots were incubated with the indicated antibodies. Band intensities normalized to loading control were indicated on top of the respec-
tive band (A, B). Similar results were obtained in duplicate experiments.
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proliferation and cell cycle arrest as observed in this
study.
However, resveratrol at lower concentrations (upto 50
μM) is not sufficient to elicit its chemotherapeutic prop-
erties in HT-29 cells. A lower dose of resveratrol is not
strong enough to induce p53 activation (Figure 7C). As a
result, the cancer cells upregulate the survival machinery
t h r o u g h  a c t i v a t i o n  o f  s u r v i v a l  p a t h w a y s  s u c h  a s  A k t /
GSK3β/Wnt signaling at low doses of resveratrol (Figure
6B). However, at lower doses of resveratrol (50 μM), there
is no significant effect on proliferation of HT-29 cells
compared to control (Figure 1). At higher concentrations
(100-150 μM), there is an elevation of activated p53 levels
and suppression of IGF-1R/Akt/Wnt signaling pathways
leading to suppressed cell proliferation, and enhanced
apoptosis. Several studies indicate that for in vitro stud-
ies, carcinogenesis-modulating effects of resveratrol
require the sustained presence of at least 5 to 100 μM
[28,30]. Even though several preclinical efficacy studies
[28,62,63] on resveratrol have reported that very low
plasma concentrations of resveratrol (20 nM - 2 μM) are
sufficient to exert potent cancer chemotherapeutic effi-
cacy and pharmacodynamic activity, such in vivo levels
would be insufficient to induce anti-carcinogenic effects
in in vitro studies. Detailed studies need to be conducted
in order to determine the dose difference in resveratrol's
anti-proliferative and pro-apoptotic effects observed in
vivo vs. in vitro.
Figure 8 Schematic diagram showing possible mechanisms by which resveratrol (RSV) alters colon cancer cell kinetics. Obesity enhances in-
sulin levels, which in turn elevates "bioactive IGF-1" levels by suppressing inhibitory IGF binding proteins (IGFBPs)-1 and -2. Activated IGF-1R phospho-
rylates a cascade of kinases PI3K, Akt and GSK3β. Phosphorylated and inactive GSK3β fails to form Axin/adenomatous polyposis coli (APC)/casein 
kinase 1 (CK1)/GSK3β destruction complex resulting in stabilization of cytosolic β-catenin and its subsequent nuclear translocation [reviewed in [64]]. 
In the nucleus, β-catenin binds to T-cell-factor 4 (TCF4) and stimulates the transcription of proliferative (e.g., cyclin D1) genes. The tumor suppressor 
p53, suppresses IGF-1R gene expression and phosphorylation. P53 attenuates IGF-1R transcription through its suppression of sp1, a critical mediator 
of IGF-1R transcription. Unphosphorylated, active FKHRL1 activates downstream target p27 and thus inhibiting cyclin D1 levels essential for cell cycle 
progression from G1 to S phase. Overall resveratrol suppresses IGF-1 induced colon cancer cell proliferation by A) downregulating IGF-1R levels, B) 
suppressing downstream IGF-1R/Akt and Wnt/β-catenin signaling C) activating p53 tumor suppressor protein, and by D) activation of FKHRL1/p27 
signaling pathways.Vanamala et al. BMC Cancer 2010, 10:238
http://www.biomedcentral.com/1471-2407/10/238
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Overall we have shown that resveratrol (i) mainly tar-
gets IGF-1R to suppress IGF-1R/Akt and Wnt/β-catenin
signaling; but does not affect IR (insulin receptor) levels,
thereby works similar to IGF-1R siRNA in suppression of
proliferation but not in the induction of apoptosis (ii) ele-
vates levels of active FKHRL1 and p27, and concomi-
tantly suppresses cyclin D1 levels and (iii) activates p53
and suppresses sp1, thereby affecting IGF-1R transcrip-
tion; thus suppressing cell cycle progression and elevating
apoptosis in vitro even in the presence of free mitogenic
IGF-1 (Figure 8).
Conclusion
In conclusion, we have shown resveratrol to suppress
IGF-1 (IGF-1 levels are elevated during obesity) induced
cell proliferation and elevate apoptosis in human colon
cancer cells, and elucidated the mechanisms of action
using IGF-1R siRNA (Figure 8). Results of the current
study will improve our understanding of the molecular
pathways involved in the chemotherapeutic intervention
of IGF-1 promoted colon tumorigenesis by the bioactive
compound resveratrol. Understanding how IGF-1, Wnt/
β-catenin and p53 pathways regulate colon cancer cell
kinetics may help in the development of new diagnostic
markers, prognostic markers, therapeutic targets and/or
evidence based safe chemotherapeutic strategies against
IGF-1 promoted cancers. We are working on detailed
mechanistic studies and generating in vivo data to further
decipher the underlying mechanism of the connection
between obesity and colon cancer.
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